Posted by Michael Wonder on 08 Dec 2021
Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics announce the initiation of rolling submission of a new drug application for CUTX-101, copper histidinate, for treatment of Menkes disease
7 December 2021 - Cyprium Therapeutics with support from its licensing partner Sentynl Therapeutics today announced the initiation of a rolling submission of a new drug application to the U.S. FDA for CUTX-101 (copper histidinate) for the treatment of Menkes disease.
The companies expect to complete the submission of the new drug application to the FDA in mid 2022.
